UPDATE: Burrill Initiates Rexahn Pharmaceuticals at Market Outperform on Promising Oncology Drug
Burrill initiated coverage on Rexahn Pharmaceuticals (NYSE: RNN) with a Market Outperform rating and a $1 price target.
Burrill commented, "We believe that Rexahn's promising pipeline in oncology and CNS disorders is undervalued, and a successful result in any of the ongoing trials may offer significant upside for investors with high risk tolerance. … Rexahn's leading oncology drug, Archexin, is a first-in-class anti-sense drug targeting the Akt-1 gene, with an orphan designation for glioblastoma, pancreatic, stomach, ovarian, and renal cancers. Rexahn has completed a Phase 2a trial in pancreatic cancer, with promising survival data in a subset of evaluable patients."
Rexahn Pharmaceuticals closed at $0.29 on Thursday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.